Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New CT scanner could spot hidden liver cancer after treatment

NCT ID NCT07351669

Diagnosis Sponsor: Zhongda Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a special type of CT scan (spectral CT) can better detect remaining liver cancer after a standard treatment called TACE. About 121 adults with liver cancer who have had TACE will get a spectral CT scan, and results will be compared to standard CT and to actual tissue samples. The goal is to see if spectral CT is more accurate at telling whether the treatment fully worked.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
spectral CT (imaging technique)
What this could lead to
If successful, spectral CT could become a more accurate way to see if liver cancer treatment worked, helping doctors decide next steps sooner.
What could go wrong
This is a small, early-stage diagnostic study, not a treatment trial. The new CT method may not prove more accurate than standard CT in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 121 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients recruited from six comprehensive medical centers nationwide

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. age 18-75 years; 2. diagnosis of HCC based on pathological findings or accepted clinical and imaging criteria; 3. Barcelona Clinic Liver Cancer (BCLC) stage A or B; 4. prior treatment with TACE; 5. undergoing contrast-enhanced spectral CT at 4-8 weeks after TACE; 6. undergoing either liver resection within 1 week after contrast-enhanced spectral CT (surgical cohort) or undergoing hepatic digital subtraction angiography (DSA) or contrast-enhanced MRI within 1 week after contrast-enhanced spectral CT (non-surgical cohort); 7. informed consent. Exclusion Criteria: 1. contraindications to contrast-enhanced CT or MRI; 2. presence of extrahepatic malignancy; 3. poor image quality or incomplete clinical data; 4. lack of regular CT or MRI follow-up in non-surgical cohort; 5. withdrawal from the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CT HCC - hepatocellular carcinoma Tace(transcatheter arterial chemoembolization)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Zhongda Hospital Southeast University

    RECRUITING

    Nanjing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.